Full-Time
Experienced Specialist in Cognitive Robotics and Neuro-AI
m/w/x
Posted on 11/23/2025
Zeiss
1,001-5,000 employees
Manufactures high-precision optical instruments and devices
No salary listed
Bellheim, Germany
In Person
 Mechanical Engineering (2) |
|---|
| , |
- PhD in Cognitive Robotics, Computational Neuroscience, AI, or related field
- Strong publication record in peer-reviewed international journals/conferences
- Deep knowledge in at least one of the following: Neuro-inspired AI and learning systems or Cognitive architectures and adaptive robotics or Multimodal signal processing and neurodecoding
- Programming experience in Python and/or C++, ROS
- Experience with robotic platforms or intelligent systems in real-world contexts
- Ideally: exposure to neurotechnology or neural data (e.g. EEG, MEG, sEEG, fNIRS, MRI)
- Guide the development of neuro-inspired architectures for adaptive robotic systems
- Design learning-enabled control and perception pipelines for complex environments
- Apply neuroscience to develop intelligent, embodied systems that exhibit robust adaptation
- Integrate multimodal data, e.g., EEG, MEG, fNIRS, SEEG, and MRI, into cognitive control loops
- Produce noteworthy publications, patents, and demonstrators
- Work together with teams in medical robotics, AI, and neurotechnology
- Mentor students and junior researchers in a collaborative and challenging environment
- A self-driven, pragmatic, and solution-oriented mindset
- Solid analytical and organizational competencies
- Commitment to push limits and establish a lasting legacy in neuro-AI and robotics
- Highly effective English communication
- A collaborative spirit and passion for interdisciplinary innovation
- Ideally: exposure to neurotechnology or neural data (e.g. EEG, MEG, sEEG, fNIRS, MRI)
ZEISS is a global leader in optics and optoelectronics, serving medical professionals, industrial manufacturers, consumers, and the semiconductor industry. It designs and sells high-precision optical instruments, medical devices, semiconductor manufacturing equipment, and vision care products such as corrective lenses and eye-health services. Its products rely on advanced optics and imaging technologies to deliver accurate inspection, diagnosis, and manufacturing outcomes across healthcare, industrial quality control, consumer optics, and chip fabrication. What sets ZEISS apart is its breadth and depth: a long-standing scale in multiple markets, integrated solutions across optics, imaging, metrology, and precision engineering, and a commitment to sustainability in electricity use and carbon emissions. The company’s goal is to advance optics and optoelectronics by providing reliable, high-quality tools and services worldwide while operating in a sustainable way.
Company Size
1,001-5,000
Company Stage
Growth Equity (Non-Venture Capital)
Total Funding
$1.1B
Headquarters
Oberkochen, Germany
Founded
2001
Simplify's Take
What believers are saying
- NMPA approval accelerates ARTEVO 750/850 sales in China's ophthalmic market.
- Collaborative Care app boosts data sharing, capturing digital health interoperability growth.
- CALYPSO 2024 software upgrade generates recurring revenue from CMM customers.
What critics are saying
- TSMC and Samsung capex cuts collapse Semiconductor Manufacturing Technology revenue.
- Suoer and Kangyang erode ARTEVO pricing in saturated Chinese microscope market.
- CLINIC 360 FDA delays stall AI diagnostic platform commercialization.
What makes Zeiss unique
- ZEISS leads in AI-powered ophthalmic tools like VisioGen and ARTEVO microscopes.
- Balanced revenue across semiconductor, medical, industrial, and consumer optics segments.
- 175-year legacy drives precision innovations in four global business segments.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
Paid Vacation
Performance Bonus
Company News
ZEISS has unveiled new digital, AI and surgical innovations for cataract and refractive workflows at the ASCRS conference. The medical technology company is expanding its US cataract portfolio with new irrigation/aspiration handpieces compatible with the DORC EVA NEXUS surgical system, alongside enhanced IOL calculation capabilities for the ZEISS IOLMaster 700. ZEISS also launched VisioGen commercially in the US, a human-verified AI patient engagement platform for ophthalmology practices. The platform integrates with clinic websites to capture patient demand around the clock, with AI-assisted responses reviewed by ZEISS-trained optometrists before delivery. The company showcased ZEISS Collaborative Care, a cloud-based application enabling secure data sharing between eye care professionals, and previewed ZEISS CLINIC 360, pending FDA clearance. ZEISS is celebrating 100 years of US operations this year.
ZEISS Medical Technology has expanded its ophthalmic workflow portfolio in Canada with new diagnostic, visualisation and therapeutic solutions. The company will showcase the innovations at upcoming Canadian ophthalmology conferences in Ottawa and Montréal. Key additions include ICGA for ZEISS CLARUS 700, offering simultaneous FA and ICG capture for clinical assessment, and ZEISS VISULAS green with selective laser trabeculoplasty for retinal photocoagulation. The company has introduced refraction devices ZEISS VISUREF 600 and ZEISS VISUCORE 500 to streamline diagnostic workflows. ZEISS also launched VISULAS yag, a new-generation therapeutic laser for anterior segment photodisruption within cataract workflows. The ZEISS FORUM subscription package, now available in Canada, offers integrated data management with unlimited device licences and lower upfront costs.
ZEISS Medical Technology has launched Collaborative Care, a browser-based application enabling eye care professionals to share data securely, refer patients and coordinate clinical care. Built on the ZEISS Health Data Platform, the solution addresses fragmented data sharing and inefficient referral processes in ophthalmic care. The application offers flexible deployment as either a standalone cloud solution or an integrated extension of ZEISS FORUM. Key features include secure exchange of images and reports, streamlined referral workflows with tracking capabilities, and tools for building professional networks between optometrists and ophthalmologists. ZEISS Collaborative Care was demonstrated at industry events in London and Orlando in February and March 2026. The company generated €2,228 million in revenue in fiscal year 2024/25 with 5,784 employees worldwide.
Custom Surgical, a German ophthalmology company, has raised €3.5 million to advance its platform. The funding will support development of AI-powered features including automated image optimisation and assisted triage processes that help determine case urgency and specialist assignment. The company is already developing its first AI-based triage and screening system. The technology aims to provide initial assessments that guide decisions on how urgently cases need attention and which medical professionals should handle them next.
Mindpeak, an AI-driven pathology startup, raised $15.3 million in a Series A round led by ZEISS Ventures and InnoVentureFund in 2024. The funding will accelerate development and deployment of the company's AI diagnostic tools for cancer pathology. Founded in 2018, Mindpeak's algorithms have supported over 30,000 patient diagnoses across US and European healthcare markets. The technology uses automated histological analyses to help pathologists make faster, more precise clinical decisions. CEO Felix Faber stated the capital would expedite product rollouts and expand capabilities. The company has established strategic partnerships with major players including Roche. Mindpeak operates in the rapidly growing digital pathology market, driven by technological innovation and increasing demand for advanced diagnostic services in an ageing population.